Drug research

Selinexor

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as KPT-330; XPOVIO; XPOVIO®; Xpovio

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389	KPTI	Phase 3	Active not recruiting	2026-02-20Actual
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870	KPTI	Phase 2	Active not recruiting	2026-09Estimated
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaNCT03110562	KPTI	Phase 3	Completed	2020-02-18Actual
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsNCT04854434	KPTI	Phase 2	Terminated	2022-06-24Actual
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931	KPTI	Phase 3	Active not recruiting	2026-08Estimated
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.NCT04414475	KPTI	Phase 2	Recruiting	2028-01Estimated
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaNCT04768881	KPTI	Phase 2	Terminated	2023-09-22Actual
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NCT02227251	KPTI	Phase 2	Active not recruiting	2026-12Estimated
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]NCT03555422	KPTI	Phase 3	Completed	2022-01-22Actual

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

KPTIActive not recruitingPrimary completion: 2026-02-20 · Actual

Trial details

Registry ID: NCT04562389
Phase: Phase 3

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

KPTIActive not recruitingPrimary completion: 2026-09 · Estimated

Trial details

Registry ID: NCT04562870
Phase: Phase 2

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

KPTICompletedPrimary completion: 2020-02-18 · Actual

Trial details

Registry ID: NCT03110562
Phase: Phase 3

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

KPTITerminatedPrimary completion: 2022-06-24 · Actual

Trial details

Registry ID: NCT04854434
Phase: Phase 2

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

KPTIActive not recruitingPrimary completion: 2026-08 · Estimated

Trial details

Registry ID: NCT05611931
Phase: Phase 3

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

KPTIRecruitingPrimary completion: 2028-01 · Estimated

Trial details

Registry ID: NCT04414475
Phase: Phase 2

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

KPTITerminatedPrimary completion: 2023-09-22 · Actual

Trial details

Registry ID: NCT04768881
Phase: Phase 2

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

KPTIActive not recruitingPrimary completion: 2026-12 · Estimated

Trial details

Registry ID: NCT02227251
Phase: Phase 2

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

KPTICompletedPrimary completion: 2022-01-22 · Actual

Trial details

Registry ID: NCT03555422
Phase: Phase 3

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.